FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148394020> ?p ?o ?g. }

• W3148394020 endingPage "963" @default.
• W3148394020 startingPage "954" @default.
• W3148394020 abstract "We previously reported CHFR methylation in a subset of colorectal cancer (CRC; ∼30%) with high concordance with microsatellite instability (MSI). We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI-high phenotypes were sensitive to gemcitabine. We hypothesized that this subset of patients with CRC would be selectively sensitive to gemcitabine and docetaxel. We enrolled a Phase 2 trial of gemcitabine and docetaxel in patients with MSI-high and/or CHFR methylated CRC. The primary objective was Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response rate. Enrolled patients were treated with gemcitabine 800 mg/m2 on days 1 and 8 and docetaxel 70 mg/m2 on day 8 of each 21-day cycle. A total of 6 patients with CHFR-methylated, MSI-high CRC were enrolled from September 2012 to August 2016. The study was closed in September of 2017 due to poor accrual prior to reaching the first interim assessment of response rate, which would have occurred at 10 patients. No RECIST criteria tumor responses were observed, with 3 patients (50%) having stable disease as best response, 1 lasting more than 9 months. Median progression-free survival (PFS) was 1.79 months (95% confidence interval [CI] = 1.28, not available [NA]) and median overall survival (OS) was 15.67 months (95% CI = 4.24, NA). Common grade 3 toxicities were lymphopenia (67%), leukopenia (33%), and anemia (33%). Although negative, this study establishes a proof-of-concept for the implementation of epigenetic biomarkers (CHFR methylation/MSI) as inclusion criteria in a prospective clinical trial to optimize combinatorial strategies in the era of personalized medicine. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? CHFR silencing via DNA methylation has been suggested to be predictive of taxane sensitivity in diverse tumors. The frequent association of CHFR methylation with microsatellite instability (MSI) suggested a possible combination therapy with gemcitabine, because the MSI phenotype may result in sensitivity to nucleoside analogues. WHAT QUESTION DID THIS STUDY ADDRESS? We hypothesized that metastatic colorectal cancer (mCRC), which have CHFR methylation and MSI phenotype were sensitive to gemcitabine and docetaxel, and have designed this Phase 2 trial in biomarker-selected mCRC to test this prediction. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? The study enrolled a molecularly defined subgroup of patients with colorectal cancer (CRC) and showed that the combination is safe in this population. Nevertheless, due to poor enrollment and early termination, no conclusions on the primary and secondary end points could be made. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? This study supports the feasibility of implementing DNA methylation markers in a prospective clinical trial and further efforts toward their application as predictive biomarkers for therapeutic agents in defined subsets of patients are warranted." @default.
• W3148394020 created "2021-04-13" @default.
• W3148394020 creator A5012480483 @default.
• W3148394020 creator A5027525899 @default.
• W3148394020 creator A5038831545 @default.
• W3148394020 creator A5047331780 @default.
• W3148394020 creator A5052412880 @default.
• W3148394020 creator A5052514925 @default.
• W3148394020 creator A5056819375 @default.
• W3148394020 creator A5060219345 @default.
• W3148394020 creator A5060234674 @default.
• W3148394020 creator A5064127666 @default.
• W3148394020 creator A5068695791 @default.
• W3148394020 creator A5077703892 @default.
• W3148394020 creator A5082233286 @default.
• W3148394020 creator A5088673015 @default.
• W3148394020 creator A5090054973 @default.
• W3148394020 date "2021-04-03" @default.
• W3148394020 modified "2023-10-14" @default.
• W3148394020 title "A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype" @default.
• W3148394020 cites W1526432021 @default.
• W3148394020 cites W1846314968 @default.
• W3148394020 cites W1851645990 @default.
• W3148394020 cites W1890647543 @default.
• W3148394020 cites W1940241680 @default.
• W3148394020 cites W1975476791 @default.
• W3148394020 cites W1985407849 @default.
• W3148394020 cites W1989478892 @default.
• W3148394020 cites W1994465394 @default.
• W3148394020 cites W2000156285 @default.
• W3148394020 cites W2019607817 @default.
• W3148394020 cites W2035554677 @default.
• W3148394020 cites W2035864521 @default.
• W3148394020 cites W2040257851 @default.
• W3148394020 cites W2041545409 @default.
• W3148394020 cites W2043414143 @default.
• W3148394020 cites W2045739820 @default.
• W3148394020 cites W2054175056 @default.
• W3148394020 cites W2056918422 @default.
• W3148394020 cites W2061955595 @default.
• W3148394020 cites W2062856589 @default.
• W3148394020 cites W2080820783 @default.
• W3148394020 cites W2091245426 @default.
• W3148394020 cites W2105100844 @default.
• W3148394020 cites W2106836326 @default.
• W3148394020 cites W2110845635 @default.
• W3148394020 cites W2111807726 @default.
• W3148394020 cites W2117424291 @default.
• W3148394020 cites W2127951115 @default.
• W3148394020 cites W2134591140 @default.
• W3148394020 cites W2144476611 @default.
• W3148394020 cites W2146797337 @default.
• W3148394020 cites W2147000771 @default.
• W3148394020 cites W2159885083 @default.
• W3148394020 cites W2164274198 @default.
• W3148394020 cites W2168680994 @default.
• W3148394020 cites W2169453999 @default.
• W3148394020 cites W2177569300 @default.
• W3148394020 cites W2262414037 @default.
• W3148394020 cites W2328946792 @default.
• W3148394020 cites W2470575266 @default.
• W3148394020 cites W2739132742 @default.
• W3148394020 cites W2766630611 @default.
• W3148394020 cites W2792555273 @default.
• W3148394020 cites W2796494201 @default.
• W3148394020 cites W2889646458 @default.
• W3148394020 cites W2892812402 @default.
• W3148394020 doi "https://doi.org/10.1111/cts.12960" @default.
• W3148394020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8212722" @default.
• W3148394020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33811727" @default.
• W3148394020 hasPublicationYear "2021" @default.
• W3148394020 type Work @default.
• W3148394020 sameAs 3148394020 @default.
• W3148394020 citedByCount "5" @default.
• W3148394020 countsByYear W31483940202022 @default.
• W3148394020 countsByYear W31483940202023 @default.
• W3148394020 crossrefType "journal-article" @default.
• W3148394020 hasAuthorship W3148394020A5012480483 @default.
• W3148394020 hasAuthorship W3148394020A5027525899 @default.
• W3148394020 hasAuthorship W3148394020A5038831545 @default.
• W3148394020 hasAuthorship W3148394020A5047331780 @default.
• W3148394020 hasAuthorship W3148394020A5052412880 @default.
• W3148394020 hasAuthorship W3148394020A5052514925 @default.
• W3148394020 hasAuthorship W3148394020A5056819375 @default.
• W3148394020 hasAuthorship W3148394020A5060219345 @default.
• W3148394020 hasAuthorship W3148394020A5060234674 @default.
• W3148394020 hasAuthorship W3148394020A5064127666 @default.
• W3148394020 hasAuthorship W3148394020A5068695791 @default.
• W3148394020 hasAuthorship W3148394020A5077703892 @default.
• W3148394020 hasAuthorship W3148394020A5082233286 @default.
• W3148394020 hasAuthorship W3148394020A5088673015 @default.
• W3148394020 hasAuthorship W3148394020A5090054973 @default.
• W3148394020 hasBestOaLocation W31483940201 @default.
• W3148394020 hasConcept C104317684 @default.
• W3148394020 hasConcept C121608353 @default.
• W3148394020 hasConcept C126322002 @default.
• W3148394020 hasConcept C143998085 @default.
• W3148394020 hasConcept C180754005 @default.

• next